{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:16:09Z","timestamp":1776453369335,"version":"3.51.2"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The prognosis of patients with refractory or relapsed AML (R\/R\u2010AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Our retrospective, single\u2010center study of 53 R\/R\u2010AML patients with a median follow\u2010up time of 11.0\u2009months compared standard salvage chemotherapy (FLAG\u2010Ida or HAM in <jats:italic>n<\/jats:italic>\u2009=\u200935 patients) with a combination of venetoclax (VEN) and FLAG\u2010Ida (FLAVIDA in <jats:italic>n<\/jats:italic>\u2009=\u200918 patients) concerning safety and efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Regarding the primary endpoints, there was a statistically significant increased event\u00a0free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log\u2010rank\u2010test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III\u00b0 and IV\u00b0 or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The FLAVIDA regimen represents a promising treatment alternative for R\/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14302","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T02:40:14Z","timestamp":1725936014000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Venetoclax Combined With <scp>FLAG<\/scp>\u2010<scp>IDA<\/scp> in Refractory or Relapsed Acute Myeloid Leukemia"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-8563","authenticated-orcid":false,"given":"Kai","family":"Wille","sequence":"first","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Dumke","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Wilsdorf","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvis","family":"Sadjadian","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Schneider","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Jender\u2010Bartling","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Kolatzki","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Horstmann","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Meixner","sequence":"additional","affiliation":[{"name":"Core Facility Statistical Consulting Helmholtz Zentrum M\u00fcnchen  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Jim\u00e9nez\u2010Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Core Facility Statistical Consulting Helmholtz Zentrum M\u00fcnchen  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Core Facility Statistical Consulting Helmholtz Zentrum M\u00fcnchen  Munich Germany"},{"name":"Faculty of Business Administration and Economics Bielefeld University  Bielefeld Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans\u2010Joachim","family":"Tischler","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum  Minden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.6.1203.1203"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623447"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8500"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000572"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1508670"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3304-y"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27618"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.243"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00572"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03736"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04883-y"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159962"},{"issue":"1","key":"e_1_2_10_18_1","first-page":"72","article-title":"Fludarabine, Cytarabine, and Idarubicin With or Without Venetoclax in Patients With Relapsed\/Refractory Acute Myeloid Leukemia","volume":"109","author":"Shahswar R.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16268"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3027-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:02:14Z","timestamp":1757322134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/ejh.14302"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14302","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"2024-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}